331 related articles for article (PubMed ID: 30007443)
1. Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry.
Rifkin RM; Jagannath S; Durie BGM; Narang M; Terebelo HR; Gasparetto CJ; Toomey K; Hardin JW; Wagner L; Parikh K; Abouzaid S; Srinivasan S; Kitali A; Zafar F; Abonour R
Clin Ther; 2018 Jul; 40(7):1193-1202.e1. PubMed ID: 30007443
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
3. Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM.
Jagannath S; Abonour R; Durie BGM; Narang M; Terebelo HR; Gasparetto CJ; Toomey K; Hardin JW; Wagner L; Agarwal A; Srinivasan S; Kitali A; Flick ED; Sturniolo M; Rifkin RM
Blood Adv; 2018 Jul; 2(13):1608-1615. PubMed ID: 29986853
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Jackson GH; Davies FE; Pawlyn C; Cairns DA; Striha A; Collett C; Hockaday A; Jones JR; Kishore B; Garg M; Williams CD; Karunanithi K; Lindsay J; Jenner MW; Cook G; Russell NH; Kaiser MF; Drayson MT; Owen RG; Gregory WM; Morgan GJ;
Lancet Oncol; 2019 Jan; 20(1):57-73. PubMed ID: 30559051
[TBL] [Abstract][Full Text] [Related]
5. Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response.
Mina R; Petrucci MT; Corradini P; Spada S; Patriarca F; Cerrato C; De Paoli L; Pescosta N; Ria R; Malfitano A; Musto P; Baldini L; Guglielmelli T; Gamberi B; Mannina D; Benevolo G; Zambello R; Falcone AP; Palumbo A; Nagler A; Calafiore V; Hájek R; Spencer A; Boccadoro M; Bringhen S
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):533-540. PubMed ID: 29910180
[TBL] [Abstract][Full Text] [Related]
6. Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry.
Abonour R; Wagner L; Durie BGM; Jagannath S; Narang M; Terebelo HR; Gasparetto CJ; Toomey K; Hardin JW; Kitali A; Gibson CJ; Srinivasan S; Swern AS; Rifkin RM
Ann Hematol; 2018 Dec; 97(12):2425-2436. PubMed ID: 30056582
[TBL] [Abstract][Full Text] [Related]
7. [Autologous stem cell transplantation improves outcomes of patients with multiple myeloma receiving proteasome inhibitors and lenalidomide treatment].
Ning X; Wei X; Guo X; Wei Q; Huang F; Fan Z; Xu N; Sun J; Feng R; Liu Q; Wei Y
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Aug; 41(9):1420-1425. PubMed ID: 34658359
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma.
Baertsch MA; Mai EK; Hielscher T; Bertsch U; Salwender HJ; Munder M; Fuhrmann S; Dührsen U; Brossart P; Neben K; Schlenzka J; Kunz C; Raab MS; Hillengaß J; Jauch A; Seckinger A; Hose D; Luntz S; Sonneveld P; Lokhorst H; Martin H; Goerner M; Hoffmann M; Lindemann HW; Bernhard H; Blau IW; Scheid C; Besemer B; Weisel KC; Hänel M; Dürig J; Goldschmidt H;
Blood Cancer J; 2021 Jan; 11(1):1. PubMed ID: 33414374
[TBL] [Abstract][Full Text] [Related]
9. Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial.
Jackson GH; Davies FE; Pawlyn C; Cairns DA; Striha A; Collett C; Waterhouse A; Jones JR; Kishore B; Garg M; Williams CD; Karunanithi K; Lindsay J; Allotey D; Shafeek S; Jenner MW; Cook G; Russell NH; Kaiser MF; Drayson MT; Owen RG; Gregory WM; Morgan GJ; Clinical Studies Group UNHO
Haematologica; 2021 Jul; 106(7):1957-1967. PubMed ID: 32499244
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
McCarthy PL; Holstein SA; Petrucci MT; Richardson PG; Hulin C; Tosi P; Bringhen S; Musto P; Anderson KC; Caillot D; Gay F; Moreau P; Marit G; Jung SH; Yu Z; Winograd B; Knight RD; Palumbo A; Attal M
J Clin Oncol; 2017 Oct; 35(29):3279-3289. PubMed ID: 28742454
[TBL] [Abstract][Full Text] [Related]
11. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial.
Holstein SA; Jung SH; Richardson PG; Hofmeister CC; Hurd DD; Hassoun H; Giralt S; Stadtmauer EA; Weisdorf DJ; Vij R; Moreb JS; Callander NS; van Besien K; Gentile TG; Isola L; Maziarz RT; Bashey A; Landau H; Martin T; Qazilbash MH; Rodriguez C; McClune B; Schlossman RL; Smith SE; Hars V; Owzar K; Jiang C; Boyd M; Schultz C; Wilson M; Hari P; Pasquini MC; Horowitz MM; Shea TC; Devine SM; Linker C; Anderson KC; McCarthy PL
Lancet Haematol; 2017 Sep; 4(9):e431-e442. PubMed ID: 28826616
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT.
Syed YY
Drugs; 2017 Sep; 77(13):1473-1480. PubMed ID: 28791622
[TBL] [Abstract][Full Text] [Related]
13. Autologous transplantation and maintenance therapy in multiple myeloma.
Palumbo A; Cavallo F; Gay F; Di Raimondo F; Ben Yehuda D; Petrucci MT; Pezzatti S; Caravita T; Cerrato C; Ribakovsky E; Genuardi M; Cafro A; Marcatti M; Catalano L; Offidani M; Carella AM; Zamagni E; Patriarca F; Musto P; Evangelista A; Ciccone G; Omedé P; Crippa C; Corradini P; Nagler A; Boccadoro M; Cavo M
N Engl J Med; 2014 Sep; 371(10):895-905. PubMed ID: 25184862
[TBL] [Abstract][Full Text] [Related]
14. Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.
Gambella M; Omedé P; Spada S; Muccio VE; Gilestro M; Saraci E; Grammatico S; Larocca A; Conticello C; Bernardini A; Gamberi B; Troia R; Liberati AM; Offidani M; Rocci A; Palumbo A; Cavo M; Sonneveld P; Boccadoro M; Oliva S
Cancer; 2019 Mar; 125(5):750-760. PubMed ID: 30561775
[TBL] [Abstract][Full Text] [Related]
15. Post-transplant consolidation plus lenalidomide maintenance vs lenalidomide maintenance alone in multiple myeloma: A systematic review.
Al-Ani F; Louzada M
Eur J Haematol; 2017 Dec; 99(6):479-488. PubMed ID: 28885719
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide maintenance post-transplantation in newly diagnosed multiple myeloma: real-world outcomes and costs.
Hari P; Ung B; Abouzaid S; Agarwal A; Parikh K
Future Oncol; 2019 Dec; 15(35):4045-4056. PubMed ID: 31625415
[No Abstract] [Full Text] [Related]
17. Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database.
Côté J; LeBlanc R; Mian H; Chu MP; McCurdy A; Masih-Khan E; Su J; Jimenez-Zepeda VH; Song K; Louzada M; White D; Sebag M; Reiman A; Stakiw J; Kotb R; Bergstrom D; Aslam M; Kaedbey R; Venner CP; Gul E; Reece D
Blood Cancer J; 2023 Sep; 13(1):137. PubMed ID: 37669949
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.
Mateos MV; Hernández MT; Giraldo P; de la Rubia J; de Arriba F; Corral LL; Rosiñol L; Paiva B; Palomera L; Bargay J; Oriol A; Prosper F; López J; Arguiñano JM; Quintana N; García JL; Bladé J; Lahuerta JJ; Miguel JS
Lancet Oncol; 2016 Aug; 17(8):1127-1136. PubMed ID: 27402145
[TBL] [Abstract][Full Text] [Related]
20. Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk.
de Tute RM; Pawlyn C; Cairns DA; Davies FE; Menzies T; Rawstron A; Jones JR; Hockaday A; Henderson R; Cook G; Drayson MT; Jenner MW; Kaiser MF; Gregory WM; Morgan GJ; Jackson GH; Owen RG
J Clin Oncol; 2022 Sep; 40(25):2889-2900. PubMed ID: 35377708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
